Antibody therapeutics, infectious disease research, and biotech innovation by Invivyd

  • Mikhail Vnuchkov
  • 16.11.2026
Invivyd posts third quarter 2026 financial results with recent business updates
Invivyd has released its financial results for the third quarter 2026, alongside an update on recent business activities. The company made the announcement through an official update, but further ...
  • Hanna Syniavska
  • 21.10.2026
Invivyd unveils VMS063 candidate at IDWeek for measles therapy
Invivyd announced the presentation of VMS063, a monoclonal antibody candidate aimed at the treatment and prevention of measles, at IDWeek 2026. The potential best-in-class candidate demonstrates ...
  • Yaroslav Dmytrenko
  • 29.09.2026
Invivyd reports positive topline results for VYD2311 in Phase 3 COVID-19 study
Invivyd has announced positive topline results from its LIBERTY Phase 3 study of VYD2311, indicating superior safety and tolerability compared to mRNA-based COVID-19 vaccines. The company also ...
  • Dmytro Kharkov
  • 18.06.2026
Invivyd, Inc. spotlights new data for solid organ transplant recipients in Boston
Invivyd, Inc. is set to present a subset analysis from its CANOPY trial focusing on solid organ transplant recipients at the American Transplant Congress in Boston. The presentation is part of ...
  • Andrey Mastykin
  • 15.06.2026
Invivyd, Inc. scrutinizes underexplored link between viral infections and cardiovascular inflammation
Invivyd, Inc. presents new analysis on the role of inflammation in atherothrombotic events and cardiovascular death. While the inflammatory process is increasingly recognized as a key driver of ...